BTIG analyst Mark Massaro raised the firm’s price target on Lucid Diagnostics (LUCD) to $2.50 from $2 and keeps a Buy rating on the shares. Attending the CMS meeting to discuss the merits of Medicare coverage for Lucid’s EsoGuard test, the firm heard “unanimously positive statements” from all clinicians supporting the “obvious use case” for EsoGuard, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Positive Outlook on Lucid Diagnostics’ EsoGuard Test Driven by Clinician Support and Potential Medicare Coverage
- Positive Outlook on Lucid Diagnostics Driven by EsoGuard’s Clinical Efficacy and Potential Medicare Coverage
- Lucid Diagnostics Earnings Call: Optimism Amid Challenges
- Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Justify Buy Rating
- Lucid Diagnostics Reports Q2 2025 Earnings